Why a QMS Gap Assessment is Important?

by | Nov 13, 2019 | FDA, Medical Devices, QMS, Quality Systems, Regulatory

As a medical device manufacturer, every company must establish a QMS in compliance with 21CFR 820 (if you sell in the US) or ISO 13485 [which is internationally recognized]. With this as a starting point, you might have the Quality Manual and the required procedures in place, but it is very important to keep checking for its continued compliance with the changing regulations.

A gap assessment is essential if you are considering selling your product in a new market. Companies that are currently ISO certified may think that they are satisfying all International QMS requirements; however, there are some country-specific requirements that need to be satisfied as well.

For instance, it is commonly misinterpreted that if the company is compliant with 21CFR820 and that since the FDA participates in the Medical Device Single Audit Program, the company should be able to pass an MDSAP audit. However, that is not the case. Your company needs to thoroughly assess the current QMS against the country-specific guidelines you wish to market in. This also applies to if your company is ISO 13485 certified. ISO 13485 is just one of the foundations of MDSAP but there are additional country-specific requirements that you need to comply with.

Some companies try and adopt the Internal Audit as a gap assessment tool; however, the goals and scope of an internal audit are different than that of a gap assessment and will not provide the same level of detailed outcome. A thorough gap assessment report is essential to get a complete understanding of all the missing or weak components of your QMS. A gap assessment will not only reduce the compliance risk but will also help save time and financial resources for your company in the long run.

EMMA International has the right expertise to conduct a thorough gap assessment of your system and provide you the correct approach for your path forward. Give us a call today to know how we can help you! Give us a call at 248-987-4497 or email us at info@emmainternational.com.

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This